Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 3 od 21  
Back povratak na rezultate
2021, vol. 149, br. 7-8, str. 415-421
Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra
aKlinički centar Srbije, Klinika za hematologiju, Beograd + Univerzitet u Beogradu, Medicinski fakultet
bKlinički centar Srbije, Klinika za hematologiju, Beograd
cUniverzitet u Beogradu, Medicinski fakultet + Univerzitet u Beogradu, Medicinski fakultet, Institut za medicinsku statistiku i informatiku
dUniverzitet u Beogradu, Institut za molekularnu genetiku i genetičko inženjerstvo
eUniverzitet u Beogradu, Medicinski fakultet, Institut za patološku anatomiju

e-adresavojinvukovic@yahoo.com
Projekat:
Retke bolesti: molekularna patofiziologija, dijagnostički i terapijski modaliteti i socijalni, etički i pravni aspekti (MPNTR - 41004)

Ključne reči: hronična limfocitna leukemija; skor CLL-IPI; skor PRS; skor MDACC 2011; ukupno preživljavanje; vreme do prve terapije
Sažetak
Uvod/Cilj Prognoza hronične limfocitne leukemije (HLL) značajno je unapređena u poslednje vreme. Među nekoliko prognostičkih modela čiji je cilj predviđanje vremena do prve terapije (eng. TTFT) izdvajaju se skor rizika od progresije (eng. PRS) i skor Centra za rak MD Anderson iz 2011. God. (eng. MDACC 2011), dok se internacionalni prognostički indeks za HLL (eng. CLL-IPI), iako primarno ustanovljen za predikciju ukupnog preživljavanja (eng. OS), dobro pokazao i u predikciji TTFT. Cilj ovog rada je da se ispita značaj pomenutih prognostičkih modela u pogledu predviđanja TTFT i OS. Metode Analizirana kohorta je obuhvatila 57 neselektovanih bolesnika sa HLL Univerzitetskog kliničkog centra Srbije sa prosečno agresivnijim profilom bolesti u odnosu na opštu populaciju de novo bolesnika sa HLL. Bolesnici su ocenjivani prema navedenim skorovima uz analizu TTFT i OS. Rezultati Bolesnici sa višim vrednostima CLL-IPI, PRS i MDACC 2011 primili su prvu terapiju značajno ranije u poređenju sa bolesnicima sa nižim vrednostima ovih skorova (p = 0,002, p = 0,019 i p < 0,001, redom). U multivarijantnoj analizi, MDACC 2011 i CLL-IPI su zadržali prognostički značaj u predikciji TTFT (p = 0,001, odnosno p = 0,018), dok je PRS ovaj značaj izgubio. CLL-IPI je bio jedini značajan prediktor OS u univarijantnoj (p = 0,005) i u multivarijantnoj analizi (p = 0,013). Zaključak CLL-IPI, PRS i naročito MDACC 2011 su dobri prediktori TTFT čak i u kohortama bolesnika sa agresivnijom bolešću, dok je za predikciju OS od ova tri prognostička modela CLL-IPI jedini primenljiv. Ovi rezultati pokazuju da bi prognostičke modele trebalo ispitati na bolesnicima sa HLL u različitim fazama bolesti, kakvi se sreću u realnoj kliničkoj praksi.
Reference
Baliakas, P., Hadzidimitriou, A., Sutton, L.A., Rossi, D., Minga, E., Villamor, N., et al. (2015) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia, 29(2): 329-336
Baliakas, P., Mattsson, M., Stamatopoulos, K., Rosenquist, R. (2016) Prognostic indices in chronic lymphocytic leukaemia: Where do we stand how do we proceed?. Journal of Internal Medicine, 279(4): 347-357
Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48(1): 198-206
Condoluci, A., Terzi, D.B.L., Langerbeins, P., Hoechstetter, M.A., Herling, C.D., de Paoli, L., et al. (2020) International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 135(21): 1859-1869
Delgado, J., Doubek, M., Baumann, T., Kotaskova, J., Molica, S., Mozas, P., et al. (2017) Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. American Journal of Hematology, 92(4): 375-380
Edelmann, J., Gribben, J.G. (2017) Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. Journal of Oncology Practice, 13(6): 371-377
Gentile, M., Shanafelt, T.D., Cutrona, G., Molica, S., Tripepi, G., Alvarez, I., et al. (2016) A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia, 30(6): 1440-1443
Gentile, M., Cutrona, G., Fabris, S., Pesce, E.A., Baldini, L., di Raimondo, F., et al. (2013) Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. American Journal of Hematology, 88(7): 539-544
Gentile, M., Shanafelt, T.D., Rossi, D., Laurenti, L., Mauro, F.R., Molica, S., et al. (2016) Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood, 128(16): 2093-2095
Gentile, M., Shanafelt, T.D., Mauro, F.R., Laurenti, L., Rossi, D., Molica, S., et al. (2018) Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. American Journal of Hematology, 93(2): E35-E37
Ghia, P., Stamatopoulos, K., Belessi, C., Moreno, C., Stilgenbauer, S., Stevenson, F., et al. (2007) ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia, Jan;21(1):1-3
Hallek, M. (2019) Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 94(11): 1266-1287
Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., et al. (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25): 2745-2760
Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G., Stevenson, F.K. (1999) Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia. Blood, 94(6): 1848-1854
International CLL-IPI working group (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncology, Jun; 17(6):779-90
Malcikova, J., Tausch, E., Rossi, D., Sutton, L.A., Soussi, T., Zenz, T., et al. (2018) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia, 32(5): 1070-1080
Mina, A., Sandoval, S.J., Sleiman, E., Pinilla-Ibarz, J., Awan, F.T., Kharfan-Dabaja, M.A. (2018) Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. Blood Reviews, 32(2): 159-166
Molica, S., Giannarelli, D., Levato, L., Mirabelli, R., Gentile, M., Lentini, M., Morabito, F. (2014) A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL). International Journal of Hematology, 100(3): 290-295
Molica, S., Giannarelli, D., Gentile, M., Cutrona, G., di Renzo, N., di Raimondo, F., et al. (2013) External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer, 119(6): 1177-1185
Molica, S., Giannarelli, D., Gentile, M., Cutrona, G., di Renzo, N., di Raimondo, F., et al. (2013) The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. Leukemia Research, 37(8): 943-947
Molica, S., Shanafelt, T.D., Giannarelli, D., Gentile, M., Mirabelli, R., Cutrona, G., et al. (2016) The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. American Journal of Hematology, 91(11): 1090-1095
Molica, S., Giannarelli, D., Levato, L., Mirabelli, R., Gentile, M., Morabito, F. (2017) Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): A comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). Leukemia & Lymphoma, 58(7): 1736-1739
Muchtar, E., Kay, N.E., Parikh, S.A. (2021) Early intervention in asymptomatic chronic lymphocytic leukemia. Clin Adv Hematol Oncol, 19(2): 92-103
Muñoz-Novas, C., Poza-Santaella, M., González-Gascón, Y.M.I., Hernández-Sánchez, M., Rodríguez-Vicente, A., Infante, M., et al. (2018) The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. BioMed Research International, 2018: 1-8
Parikh, S.A., Rabe, K.G., Kay, N.E., Call, T.G., Ding, W., Schwager, S.M., et al. (2014) Chronic lymphocytic leukemia in young (<= 55 years) patients: A comprehensive analysis of prognostic factors and outcomes. Haematologica, 99(1): 140-147
Parikh, S.A., Strati, P., Tsang, M., West, C.P., Shanafelt, T.D. (2016) Should IGHV status and FISH testing be performed in all CLL patients at diagnosis: A systematic review and meta-analysis. Blood, 127(14): 1752-1760
Pflug, N., Bahlo, J., Shanafelt, T.D., Eichhorst, B.F., Bergmann, M.A., Elter, T., et al. (2014) Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 124(1): 49-62
Pospisilova, S., Gonzalez, D., Malcikova, J., Trbusek, M., Rossi, D., Kater, A.P., et al. (2012) ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia, 26(7):1458-61
Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., Pasternack, B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46(2): 219-253
Rani, L., Gogia, A., Singh, V., Kumar, L., Sharma, A., Kaur, G., Gupta, R. (2019) Comparative assessment of prognostic models in chronic lymphocytic leukemia: Evaluation in Indian cohort. Annals of Hematology, 98(2): 437-443
Shanafelt, T.D., Rabe, K.G., Kay, N.E., Zent, C.S., Jelinek, D.F., Reinalda, M.S., et al. (2010) Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer, 116(20): 4777-4787
Smolej, L., Turcsányi, P., Kubová, Z., Zuchnická, J., Mihályová, J., Šimkovič, M., et al. (2021) External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. British Journal of Haematology, 193(1): 133-137
Wierda, W.G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K., et al. (2011) Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 29(31): 4088-4095
Wierda, W.G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K., et al. (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 109(11): 4679-4685
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/SARH201005047M
primljen: 05.10.2020.
revidiran: 30.04.2021.
prihvaćen: 23.05.2021.
objavljen onlajn: 28.05.2021.
objavljen u SCIndeksu: 03.09.2021.